KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Charles River Laboratories International (CRL) EBITDA (2016 - 2025)

Historic EBITDA for Charles River Laboratories International (CRL) over the last 17 years, with Q3 2025 value amounting to $133.8 million.

  • Charles River Laboratories International's EBITDA rose 1396.36% to $133.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $140.9 million, marking a year-over-year decrease of 7330.93%. This contributed to the annual value of $227.3 million for FY2024, which is 6316.84% down from last year.
  • Per Charles River Laboratories International's latest filing, its EBITDA stood at $133.8 million for Q3 2025, which was up 1396.36% from $100.1 million recorded in Q2 2025.
  • Charles River Laboratories International's 5-year EBITDA high stood at $187.4 million for Q2 2022, and its period low was -$167.7 million during Q4 2024.
  • Over the past 5 years, Charles River Laboratories International's median EBITDA value was $148.8 million (recorded in 2022), while the average stood at $126.0 million.
  • Its EBITDA has fluctuated over the past 5 years, first soared by 7917.62% in 2021, then crashed by 22615.44% in 2024.
  • Quarter analysis of 5 years shows Charles River Laboratories International's EBITDA stood at $172.8 million in 2021, then dropped by 5.21% to $163.8 million in 2022, then dropped by 18.86% to $132.9 million in 2023, then tumbled by 226.15% to -$167.7 million in 2024, then surged by 179.79% to $133.8 million in 2025.
  • Its EBITDA was $133.8 million in Q3 2025, compared to $100.1 million in Q2 2025 and $74.7 million in Q1 2025.